-

Horizon Therapeutics plc Named One of the Fortune Best Workplaces in Chicago

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the Fortune Best Workplaces in Chicago 2022 list, ranking No. 3 in the large company category. The list includes 15 top large sized companies, as well as 35 best small-to-medium workplaces in the Chicago area.

“With two offices in the Chicago area, including our U.S. headquarters, we are honored to be named by Great Place to Work to the Fortune Best Workplaces in Chicago list for the sixth year in a row,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “When we set out to build a global company to bring new therapies to patients with rare, autoimmune and severe inflammatory diseases, we knew that nurturing an authentic culture and rewarding workplace were key foundational elements. That’s why our employees receive best-in-class benefits and services to best support them and their families.”

Great Place to Work selected the Best Workplaces in Chicago by gathering and analyzing confidential survey responses from its study of thousands of companies representing more than 6.1 million U.S. employees at Great Place to Work-Certified™ organizations. Companies must be headquartered in the Chicago metropolitan statistical area to be eligible. Horizon was also recently named one of Fortune’s Top 100 Companies, making it the highest-ranking biotech on the list in 2022.

About Horizon

Horizon is a global biotechnology company focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

About Great Place to Work®

Great Place to Work® is the global authority on workplace culture. Since 1992, they have surveyed more than 100 million employees worldwide and used those deep insights to define what makes a great workplace: trust. Their employee survey platform empowers leaders with the feedback, real-time reporting and insights they need to make data-driven people decisions. Everything they do is driven by the mission to build a better world by helping every organization become a great place to work For All™. Learn more at greatplacetowork.com and on LinkedIn, Twitter, Facebook and Instagram.

Contacts

Catherine Riedel
Executive Director, Corporate Visibility and Media Strategy
media@horizontherapeutics.com

Horizon Therapeutics plc

NASDAQ:HZNP

Release Versions

Contacts

Catherine Riedel
Executive Director, Corporate Visibility and Media Strategy
media@horizontherapeutics.com

More News From Horizon Therapeutics plc

Rule 17(e) Announcement - Horizon Therapeutics plc

DUBLIN--(BUSINESS WIRE)--  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE October 6, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of...

Rule 17(d) Announcement – Horizon Therapeutics plc

DUBLIN--(BUSINESS WIRE)--  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION October 5, 2023 RECOMMENDED CASH OFFER for HORIZON THERAPEUTICS PLC by Pillartree Limited, a private limited company wholly owned by Amgen Inc. to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies A...

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)

DUBLIN--(BUSINESS WIRE)--IRISH TAKEOVER PANEL DEALING DISCLOSURE UNDER RULE 8.1(c) AND (d)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY AN OFFEROR, OFFEREE OR PARTIES ACTING IN CONCERT WITH THEM IN RESPECT OF DEALINGS FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS 1. KEY INFORMATION (a) Full name of discloser: Elizabeth Crossan (b) Owner or controller of interests and short positions disclosed, if different from 1(a):   The naming of nominee or vehicle companies is insufficien...
Back to Newsroom